Danish pharmaceutical giant Novo Nordisk, renowned for its diabetes and weight loss drugs Ozempic and Wegovy, has experienced a significant share price drop of around 19% this month. This decline follows its market peak in June, driven by increasing competition from Eli Lilly, a key player in the same space. Eli Lilly has gained substantial momentum with its rival drugs,…